|
|
4547 KISSEI PHARMACEUTICAL CO.,LTD.
|
|
09/17/2024 08:45 |
Launch of YSELTY (generic name linzagolix) for uterine fibroid treatment in Europe |
09/09/2024 14:00 |
Drug discovery research collaboration agreement with Reborna Biosciences, Inc. |
09/04/2024 08:45 |
Licensing Agreement for "olutasidenib", an Acute Myeloid Leukemia Drug |
07/30/2024 15:00 |
Supplementary Explanatory Materials on Financial Results for the Three Months Ended June 30, 2024 |
07/30/2024 15:00 |
Consolidated Financial Results for the Three Months Ended June 30, 2024 [Japanese GAAP] |
06/10/2024 16:00 |
Licensing Agreement for GnRH Antagonist Linzagolix with JW Pharmaceutical Corporation in Korea |
06/03/2024 08:00 |
Notice of Convocation Annual General Meeting 2024 |
05/08/2024 16:00 |
Financial Briefing for the Fiscal Year Ended March 31, 2024 |
05/07/2024 15:00 |
Supplementary Explanatory Materials on Financial Results for the Fiscal Year Ended March 31, 2024 |
05/07/2024 15:00 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 [Japanese GAAP] |
05/07/2024 15:00 |
Summary of Financial Results 2024 |
01/30/2024 15:00 |
Summary of Financial Results for the third quarter 2024 |
01/30/2024 15:00 |
Consolidated Financial Results for the Nine Months Ended December 31, 2023 [Japanese GAAP] |
01/30/2024 15:00 |
Supplementary Explanatory Materials on Financial Results for the Nine Months Ended December 31, 2023 |
12/12/2023 14:00 |
KORSUVA IV Injection Syringe for Dialysis to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis |
11/07/2023 10:00 |
Announcement concerning the Results of the Acquisition of Treasury Shares through ToSTNeT-3 |
11/06/2023 16:00 |
Notice concerning the Purchase of Treasury Shares through ToSTNeT-3 |
11/06/2023 16:00 |
Consolidated Financial Results for the Six Months Ended September 30, 2023 [Japanese GAAP] |
11/06/2023 16:00 |
Supplementary Explanatory Materials on Financial Results for the Six Months Ended September 30, 2023 |
10/27/2023 15:00 |
Notice Concerning Revisions to Financial Results Forecast |
09/25/2023 15:00 |
KORSUVA IV Injection Syringe Granted Marketing Authorization Approval in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis |
|